The internationally recognised drug discovery specialist has more than 35 years experience – from early compound identification to clinical Proof of Concept. In 1999, he and his colleagues from Eli Lilly received the Society for Medicines Research Award for Drug Discovery for Olanzapin, an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder. Before joining BioAscent, he was working for Charles River Discovery Services. The pre-clinical contract research organisation BioAscent was founded in 2013.

Moore is looking forward to the new challenge: "Working with customers varying from the smallest academic spin-out to large pharma, and being able to offer customised services to meet their exact requirements was a real draw for me", said Dr Moore. "BioAscent's capabilities in drug discovery and compound management are an especially good fit with VC-funded biotechs, because we offer a rare mix of leading infrastructure and scientific excellence. We can really contribute scientifically to their project teams, and also provide compound management expertise to ensure that the right compounds are shipped to the right place, at the right time, in the right format – and in the most cost-effective and trackable way."